Tirzepatide is a gastric inhibitory polypeptide analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes and for weight loss.
To summarize current knowledge about GLP-1 receptor agonist. At present, GLP-1 RAs are injected twice daily (exenatide b.i.d.), once daily (lixisenatide and liraglutide), or once weekly (exenatide once weekly, dulaglutide, albiglutide, and semaglutide).
Beyond the impressive effects of GLP-1 receptor agonists on blood glucose levels and body weight, large-scale randomized, controlled trials have shown that GLP-1 receptor agonists...
Such details provide a deeper understanding and appreciation for Glp-1 Receptor Agonist Type 2 Diabetes Clinical.
GLP-1 binds the GLP-1 Receptor located in the brain, intestines, liver, fat tissue, kidneys, heart. Once bound to the receptor, the hormone produces its effects (previous slide). The effect varies based on where the receptor is located.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were initially approved for type 2 diabetes mellitus. Recent evidence suggests their therapeutic potential in various diseases,...
Mounjaro (tirzepatide) is the first and only, once-weekly approved single-molecule GIP and GLP-1 receptor agonist that helps lower A1C for adults with type 2 diabetes.
Common Side Effects of GLP-1 Agonists. GLP-1 receptor agonists, such as semaglutide and tirzepatide, are effective medications for managing obesity and type 2 diabetes.
Recommendations from current clinical guidelines for the appropriate use of the GLP receptor agonists in the management of Type 2 diabetes. Clinically relevant differences among the current agents within the GLP drug class.
